-
Nat Med: Study reveals factors that influence immune outcomes for kidney cancer
Time of Update: 2020-06-17
, June 10, 2020 /PRNewswire/ -- Scientists at the Biovalley BIOON /-- By analyzing tumors in patients with advanced kidney cancer who received immunotherapy in three clinical trials , scientists h
-
The administration is only 3-5 minutes! Johnson and Johnson Darzalex (megazo ®) subcutaneous preparation has been approved by the European Union: the first myeloma subcutaneous CD38 target anti-cancer drug!
Time of Update: 2020-06-17
, 2020 / PRNewswire/ -- The European Commission (EC) recently approved The Johnson and Johnson (JNJ) heavy myeloma drug Darzalex ,®, generic name: daratumab, Darree Subcutaneous (SC) preparations f
-
New medicine for myeloma! Sanofi CD38 Antibody Sarclisa Combination Therapy Phase III Clinically Significantly Prolonged ProgressIon Survival, Deep Remission!
Time of Update: 2020-06-17
, June 10, 2020 / BIOON/Sanofi has announced positive results from a clinical trial of CD38-targeted antibody drug Sarclisa (isatumab) for recurrent and/or refractable multiple myeloma (MM) PHASE I
-
Nature sub-magazine breakthrough! Fasting with vitamin C is effective for hard-to-treat cancers
Time of Update: 2020-06-17
, June 6, 2020 / BioValley /PRNewswire/ -- Scientists from the University of Southern California (USC) and the IFOM Cancer Institute in Milan have found that a diet that mimics fasting may be more e
-
PNAS: Nanoparticles stimulate the immune system and help it attack tumors
Time of Update: 2020-06-17
, June 10, 2020 /PRNewswire/ -- Biovalley BIOON /- Suppresses the immune system, so these types of treatments are not suitable for all patients MIT engineers have now come up with a way to improve
-
Three-pronged treatment for three-negative breast cancer (TNBC)! BMS and UbiVac partnered with cancer vaccine DPV-001/anti-OX40/anti-PD-1 triple therapy!
Time of Update: 2020-06-17
, June 10, 2020 /PRNewswire/ -- Cancer vaccine developer UbiVac and BMS have recently reached a clinical trial partnership to evaluate a pioneering cancer vaccine, DPV-001, developed using autophagy
-
BRAF inhibitor Braftovi approved by the European Medicines Agency for the treatment of colorectal cancer in conjunction with EGFR antibody Erbitux
Time of Update: 2020-06-16
The BRAF inhibitor Braftovi (encorafenib) and EGFR-targeted antibody Erbitux (cetuximab) were approved by the European Medicines Agency for use as a second-line treatment for patients previously unde
-
Cell: Single Cell Map of Tumor stumor and immune ecosystem of human breast cancer
Time of Update: 2020-06-16
Breast cancer is a heterogeneous disease Tumor cells and associated healthy cells form ecosystems that determine disease progress and response to treatment To characterize the characteristics of the
-
Blood: A new neuroamide analogue and mechanism that can effectively inhibit invivating invivating invivating invivating invivating invivating invivating invivating invivating invivating invivating in
Time of Update: 2020-06-16
Primary oozed lymphoma (PEL) is an invasive malignant tumor with poor prognosis even in the case of active chemotherapy, usually accompanied by Kaposi sarcoma-associated herpes virus (Kaposi's sarcom
-
NEJM: Efficacy and Safety of Tepotinib in MET Exon 14 Jump Mutation in NSCLC
Time of Update: 2020-06-16
Globally, lung cancer is the most common type of cancer and the leading cause of cancer death, with 2 million cases diagnosed and 1.7 million deaths diagnosed each year MET signaling pathway changes,
-
Blood: MiR-146a deficiency links IL6/TNFD induced inflammation to myelin malignancies
Time of Update: 2020-06-16
Aging is associated with significant changes in the hematopoietic system, including increased inflammation, impaired function of hematopoietic stem cells (HSC) and increased incidence of myelin malig
-
CELL: The Wang Xinwei team found that virus exposure characterized the early incidence of liver cancer?
Time of Update: 2020-06-16
Liver cancer (HCC) is an invasive malignant tumor whose global morbidity and mortality rate continue to rise, but the early detection and monitoring effect is not satisfactory Recently, using synthe
-
Blood: Efficacy and safety of netoplasm for relapse of blood malignancies after alloHCT
Time of Update: 2020-06-16
CTLA-4 blocking enhances the anti-tumor effect of an allogeneic hematopoietic cell transplant (alloHCT) in recurrent malignant blood disease (HMs) The interaction of PD-1/PDL-1 can also lead to impai
-
Blood: Does the interval between diagnosis and the start of treatment affect the prognosis of newly diagnosed AML patients?
Time of Update: 2020-06-16
Since the prognosis of acute leukemia without treatment is poor, it is recommended that patients with newly diagnosed acute myeloid leukemia (AML) begin treatment immediately In a new article publish
-
Female, found gallbladder polyps 5 days, please diagnose!
Time of Update: 2020-06-16
"Department" hepatobiliary surgery patients, female, 37-year-old "main complaint" physical examination found that gallbladder polyps 5 days, not related treatment "current medical history" found gall
-
Blood: Effect of human-derived Fc receptor non-binding anti-CD3 monoclonal antibodies in T-ALL
Time of Update: 2020-06-16
T-cell acute lymphoblastic leukemia (T-ALL) is an invasive malignant tumor that accounts for about 20% of ALL cases Intensive chemotherapy regimens have a cure rate of more than 85%, but less than 50
-
Lancet oncol: Tafasitamab combined to the efficacy of nadoamine treatment for relapse/refractive diffuse large B cell lymphoma
Time of Update: 2020-06-16
Relapsed or refractive diffuse large B-cell lymphoma is not suitable for patients with self-contained stem cell transplantation with poor prognosis and few treatment options Tafasitamab (MOR208) is a
-
Blood: HHEX and Mutant ASXL1 work together to promote myelin transformation
Time of Update: 2020-06-16
The Additional Sex Combs-like 1, ASXL1 encodes a chromatin binding protein, an epigenetic regulatory factor that mutates frequently in myelin tumors Recent analysis of mutant ASXL1 condition knock-in
-
Blood: HLA-B pilot genotype predicts hlA mismatch with prognosis of bloodless donor HCT
Time of Update: 2020-06-16
Hematopoietic cell transplantation (HCT) from hlA mismatched non-blood-related donors can cure life-threatening blood diseases, but its success rate is limited by graft-resistant host disease (GVHD)
-
Thyroid: Metabolic Syndrome and Risk of Thyroid Cancer
Time of Update: 2020-06-16
The relationship between metabolic syndrome and its components and the risk of thyroid cancer is not clear In a recent study published in the authoritative journal Thyroid, researchers conducted a la